Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.68 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781704 | 0.95 | CHRNA7 (0.75) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL2908050 | 0.87 | CHRNA7 (0.89) | CHRNA7HTR3ACHRNA3 | |
| Fumaric Acid SCHEMBL768339 | 0.87 | CHRNA7 (0.74) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7559030 | 0.82 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNA3 | |
| Fumaric Acid SCHEMBL2291038 | 0.81 | CHRNA7 (0.69) | CHRNA7HTR3ACHRNA3 | |
| Ssr180711 SCHEMBL1944638 | 0.81 | CHRNA7 (0.85) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL1781237 | 0.80 | CHRNA7 (0.63) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL1781632 | 0.80 | CHRNA7 (0.84) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4190184 | 0.79 | CHRNA7 (0.78) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7556223 | 0.77 | CHRNA7 (0.84) | CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118268-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118268-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA6, CHRNA2, CHRNA10 | CHRNA7 6/4885HTR3A 69/4885CHRNA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.